

SUGGESTED DOSAGE FOR FVIII & FIX EXTENDED HALF-LIFE CLOTTING FACTOR CONCENTRATES FOR COUNTRIES WITH LIMITED RESOURCES

Practice patterns: peak plasma factor levels and duration of administration

Extended Half-Life Clotting Factor Concentrates

	Hemophilia A FVIII		Hemophilia B FIX	
	Peak factor level (IU>dL)	Duration of therapy	Peak factor level (IU>dL)	Duration of therapy
PROPHYLAXIS				
	10	Every 4 days	10–20	Every 7 days
	20	Every 7 days	20	Every 10 days
ON-DEMAND (EPISODIC) TREATMENT				
Mild/Moderate bleeds				
Early hemarthrosis, muscle bleeding or oral bleeding; serious hemorrhage in joints (extensive hemarthrosis), muscle bleeding or hematoma (iliopsoas, calf, and forearm)	10 Repeat infusion every 24–48 hours	Until the bleeding episode is resolved (usually 1-2 days results >90% efficacy)	10–20 Repeat infusion every 48 hours	Until the bleeding episode is resolved
Major bleeds (life threatening hemorrhages)				
Intracranial, intrathoracic, gastrointestinal, and renal	30–40 Repeat infusion every 12–24 hours	Until the bleeding episode is resolved (measure FVIII level, if level is <50–70% repeat infusion every 24 hours)	50–60 Repeat infusion every 24 hours for the first 3 days, then repeat infusion every 48–72 hours until bleeding stops	Until the bleeding episode is resolved (approximately 7–10 days)
SURGERY				
Minor (including tooth extraction)				
	20–30 Repeat infusion every 24 hours	1–3 days, depending on type of procedure	30–40 Repeat infusion every 48 hours	At least 1 day until adequate wound healing occurs
Major				
Pre-operative	30–40	Every 12–24 hours for the first 48 hours or until adequate wound healing occurs, then repeat infusion every 24–48 hours for at least 7 days	40–60	Every 12 hours for the first 24 hours or until adequate wound healing occurs, then repeat infusion every 48 hours for at least 7 days
Post-operative	20 After 12 hours and then every 24 hours		20–40 Every 24–48 hours	

Disclaimers

- The doses above are an extrapolation of Chapter 7 of the WFH Guidelines for the Management of Hemophilia and have not been evaluated through a formal assessment of the evidence by the guideline panels.
- The World Federation of Hemophilia does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals.
- Dose schedules and other treatment regimes are continually revised and new side effects recognized. For these reasons it is strongly recommended that individuals seek the advice of a medical healthcare provider.

For further information please contact Assad Haffar, MD, WFH Medical Director

Tel: +1 (514) 875-7944 #2830 ■ Email: ahaffar@wfh.org